Which surgery needs to be used in the Differentiated Thyroid Carcinoma?

Antonella Pino, Ettore Caruso, Antonina Catalfamo, Fausto Famà, Francesca Pia Pergolizzi, Alessandro Pontin, Gianlorenzo Dionigi

Abstract


Surgery for thyroid carcinoma involves a complex decision-making process and technical skills, both related to the experience of the endocrinologist and surgeon. Based on a stratified risk approach for the management of differentiated thyroid carcinoma, therapeutic decisions can now be divided into active surveillance or immediate surgery, e.g. hemithyroidectomy with isthmectomy, total thyroidectomy, or thyroidectomy and locoregional lymphadenectomy. Total thyroidectomy is a surgery associated with high rates of healing and has been considered the gold standard for years. However, thyroid lobectomy, in selected cases, is now recognized as equally oncologically effective and is associated with decreased morbidity in appropriately selected patients. The morbidity of the prophylactic lymphadenectomy of the central compartment is significant in terms of transient and permanent hypocalcaemia. This led to a less aggressive prophylactic surgical approach in the recent guidelines of the American Thyroid Association of 2015.  Re-operations in the central or lateral compartment can be difficult and lead to an increased risk to the patient. Therefore, it is important to perform an optimal initial operation in every patient with thyroid cancer. Consideration should be given to addressing patients with high-risk characteristics (N1 clinical disease, locally invasive disease) to experienced surgeons, both for oncologic completeness and for significant impact on clinical outcomes and complication rates.

Keywords


thyroid; thyroid cancer; differentiated thyroid carcinoma; papillary carcinoma; follicular carcinoma; surgery; endoscopic surgery; recurrence; pediatric surgery

Full Text:

PDF

References


References

Cancer Research UK. Cancer incidence for common cancers. http://www.cancerresearchuk.org/cancer-info/cancerstats/incidence/commoncancers/#Trends.

National Cancer Institute Surveillance Epidemiology and End Results. Thyroidfact sheet. http://seer.cancer.gov/statfacts/html/thyro.html.

Enewold, L., Zhu, K., Ron, E., et al. Rising thyroid cancer incidence in the UnitedStates by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev2009;18:784–91.

Udelsman, R., Zhang, Y. The epidemic of thyroid cancer in the United States: therole of endocrinologists and ultrasounds. Thyroid 2014;24:472–9.

Chen, A.Y., Jemal, A., Ward, E.M. Increasing incidence of differentiated thyroid cancerin the United States, 1988-2005. Cancer 2009;115:3801–7.

Pellegriti, G., Frasca, F., Regalbuto, C., Squatrito, S., Vigneri,R..Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212. doi: 10.1155/2013/965212.

Pellegriti, G., De Vathaire, F., Scollo, C., Attard, M., Giordano, C., Arena, S., Dardanoni, G., Frasca, F., Malandrino, P., Vermiglio, F., Previtera, D.M., D'Azzò, G., Trimarchi, F., Vigneri, R. Papillarythyroidcancerincidence in the volcanic area of Sicily. J Natl Cancer Inst. 2009 Nov 18;101(22):1575-83. doi: 10.1093/jnci/djp354. Epub 2009 Nov 5. PubMed PMID: 19893009.

Lim, H., Devesa, S.S., Sosa, J.A., Check, D., Kitahara, C.M. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338–1348. doi:10.1001/jama.2017.2719

Sosa, J.A., Bowman, J.M., Tielsch, J.M., et al. The importance of surgeon experiencefor clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228: 320–30.

Pacini, F. Management of papillary thyroid microcarcinoma: primum non nocere!J ClinEndocrinolMetab2013;98:1391–3.

Dionigi, G.,Barlatena, L., Cantano, G., Dionigi, R. Tiroide. 211-231. In Chirurgia. Ed. Dionigi. 2016. Edra Spa. Milano

Haugen, B.R., Alexander, E.K., Bible, K.C., Doherty, G.M., Mandel, S.J., Nikiforov, Y.E., Pacini, F., Randolph, G.W., Sawka, A.M., Schlumberger, M., Schuff, K.G., Sherman, S.I., Sosa, J.A., Steward, D.L., Tuttle, R.M., Wartofsky, L. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated ThyroidCancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodulesand Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. doi:10.1089/thy.2015.0020. Review. PubMed PMID: 26462967; PubMed Central PMCID: PMC4739132.

Cibas, E.S., Ali, S.Z. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017 Nov;27(11):1341-1346. doi: 10.1089/thy.2017.0500. PubMed PMID: 29091573.

Nardi, F., Basolo, F., Crescenzi, A., Fadda, G., Frasoldati, A., Palombini, L., Orlandi, F., Papini, E., Zini, M.,Pontecorvi, A., Vitti, P. ItalianConsensus for the classification and reporting of thyroidcytology. 2014 J EndocrinolInvest DOI 10.1007/s40618-014-0062-0.

Randolph, G.W. The importance of pre- and postoperative laryngeal examinationfor thyroid surgery. Thyroid. 2010 May;20(5):453-8. doi: 10.1089/thy.2010.1632.PubMed PMID: 20450429.

Randolph, G.W., Kamani, D. The importance of preoperative laryngoscopy in patientsundergoing thyroidectomy: voice, vocal cord function, and the preoperativedetection of invasive thyroid malignancy. Surgery. 2006 Mar;139(3):357-62. PubMed PMID: 16546500.

Dionigi, G., Boni, L., Rovera, F., Rausei, S., Castelnuovo, P., Dionigi, R. Postoperative laryngoscopy in thyroid surgery: proper timing to detect recurrent laryngealnerve injury. Langenbecks Arch Surg. 2010 Apr;395(4):327-31. doi: 10.1007/s00423-009-0581-x. Epub 2009 Dec 15. PubMed PMID: 20013128.

Choi, J.S., Kim, J., Kwak, J.Y., Kim, M.J., Chang, H.S., Kim, E.K. 2009 Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol 193:871–878.

Lesnik, D., Cunnane,M.E., Zurakowski, D., Acar, G.O., Ecevit, C., Mace, A., Kamani, D., Randolph,G.W. Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients. Head Neck 2014 36:191–202.

Haugen, B.R., Alexander, E.K., Bible, K.C., Doherty, G.M., Mandel, S.J., Nikiforov, Y.E., Pacini, F., Randolph, G.W., Sawka, A.M., Schlumberger, M., Schuff, K.G., Sherman, S.I., Sosa, J.A., Steward, D.L., Tuttle, R.M., Wartofsky, L. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated ThyroidCancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodulesand Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. doi:10.1089/thy.2015.0020. Review. PubMed PMID: 26462967; PubMed Central PMCID: PMC4739132.

Hay, I.D., Bergstralh, E.J., Goellner, J.R., Ebersold, J.R., Grant, C.S. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993114: 1050–1057.

Shah, M.D., Hall, F.T., Eski, S.J., Witterick, I.J., Walfish, P.G., Freeman, J.L. Clinical course of thyroid carcinoma after neck dissection. Laryngoscope 2003 113:2102–2107.

Wang, T.S., Dubner, S., Sznyter, L.A., Heller, K.S. Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes. Arch Otolaryngol Head Neck Surg 2004 130:110–113.

Mazzaferri, E.L. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. EndocrPract 2000. doi:6:469–476.

Hay, I.D., Thompson, G.B., Grant,C.S,.Bergstralh, E.J., Dvorak, C.E., Gorman, C.A., Maurer, M.S., McIver, B., Mullan, B.P., Oberg, A.L., Powell, C.C., van Heerden, J.A., Goellner, J.R. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 con- secutively treated patients. World J Surg 2002 26:879–885.

Castagna, M.G., Forleo, R., Maino, F., Fralassi, N., Barbato, F., Palmitesta, P., Pilli, T., Capezzone, M., Brilli, L., Ciuoli, C., Cantara, S., Formichi, C., Pacini, F. Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor. J Endocrinol Invest. 2018 Feb 22. doi: 10.1007/s40618-018-0854-8.[Epub ahead of print] PubMed PMID: 29470826.

Pacini, F. Which patient with thyroid cancer deserves systemic therapy andwhen? Best Pract Res ClinEndocrinolMetab. 2017 Jun;31(3):291-294. doi: 10.1016/j.beem.2017.08.001. Epub 2017 Aug 18. Review. PubMed PMID: 28911725.

Dal Maso, L., Tavilla, A., Pacini, F., Serraino, D., van Dijk, B.A.C., Chirlaque, M.D.,Capocaccia, R., Larrañaga, N., Colonna, M., Agius, D., Ardanaz, E., Rubió-Casadevall, J.,Kowalska, A., Virdone, S., Mallone, S., Amash, H., De Angelis, R.; EUROCARE-5 Working Group. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. Eur J Cancer. 2017 May;77:140-152. doi: 10.1016/j.ejca.2017.02.023. Epub 2017 Apr 11. PubMed PMID: 28410490.

Pacini, F., Brianzoni, E., Durante, C., Elisei, R., Ferdeghini, M., Fugazzola, L., Mariotti, S., Pellegriti, G. Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. J Endocrinol Invest. 2016 Mar;39(3):341-7. doi: 10.1007/s40618-015-0375-7. Epub 2015 Aug 12. PubMed PMID: 26264386; PubMed Central PMCID: PMC4761012.

Pacini, F., Castagna, M.G. Approach to and treatment of differentiated thyroidcarcinoma. Med Clin North Am. 2012 Mar;96(2):369-83. doi:10.1016/j.mcna.2012.01.002. Epub 2012 Feb 10. Review. PubMed PMID: 22443981.

Leboulleux, S., Tuttle, R.M., Pacini, F., Schlumberger, M. Papillary thyroidmicrocarcinoma: time to shift from surgery to active surveillance? LancetDiabetes Endocrinol. 2016 Nov;4(11):933-942. doi: 10.1016/S2213-8587(16)30180-2. Epub 2016 Aug 20. Review. PubMed PMID: 27550849.

Bilimoria, K.Y., Bentrem, D.J., Ko, C.Y., et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg2007;246:375–81.

Nixon, I.J., Ganly, I., Patel, S.G., et al. Thyroid lobectomy for treatment of well differ- entiatedintrathyroid malignancy. Surgery 2012;151:571–9.

Hay, I.D. Papillary thyroid carcinoma. EndocrinolMetabClin North Am 1990;19: 545–76.

Viola, D., Materazzi, G., Valerio, L., Molinaro, E., Agate, L., Faviana, P., Seccia, V., Sensi, E., Romei, C., Piaggi, P., Torregrossa, L., Sellari-Franceschini, S., Basolo, F., Vitti, P., Elisei, R., Miccoli, P. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from thefirst prospective randomized controlled single institution study. J ClinEndocrinolMetab. 2015 Apr;100(4):1316-24. doi: 10.1210/jc.2014-3825. Epub 2015Jan 15. PubMed PMID: 25590215.

Carling, T., Long, W.D. 3rd, Udelsman, R. Controversy surrounding the role for routine central lymph node dissection for differentiated thyroid cancer. CurrOpinOncol2010;22:30–4.

Bonnet, S., Hartl, D., Leboulleux, S., et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J ClinEndocrinolMetab2009;94:1162–7.

Feuerstein, J.D., Akbari, M., Gifford, A.E., Hurley, C.M., Leffler, D.A., Sheth, S.G., Cheifetz, A.S. Systematic analysis underlying the quality of the scientific evidence and conflicts of interest in interventional medicine subspecialty guidelines. Mayo Clin Proc. 2014 Jan;89(1):16-24. doi: 10.1016/j.mayocp.2013.09.013. PubMed PMID: 24388018.

Roman, S., Boudourakis, L., Sosa, J.A. Health services research in endocrine surgery. CurrOpinOncol2008;20:47–51.

Pacini, F. Observation for newly diagnosed micro-papillary thyroid cancer: isnow the time? J Endocrinol Invest. 2015 Jan;38(1):101-2. doi:10.1007/s40618-014-0200-8. Epub 2014 Oct 26. Review. PubMed PMID: 25344825.

Pacini, F. Thyroid microcarcinoma. Best Pract Res ClinEndocrinolMetab. 2012 Aug;26(4):421-9. doi: 10.1016/j.beem.2012.07.001. Epub 2012 Jul 15. Review. PubMed PMID: 22863385.

Pacini, F. Changing natural history of differentiated thyroid cancer.Endocrine. 2012 Oct;42(2):229-30. PubMed PMID: 22736408.

Shaha, A.R., Tuttle, R.M. Editorial: risk of disease progression during active 80 surveillance of papillary thyroid cancer. Surgery 2018;163:53-4. 81 2.

Perlis, N., Klotz, L. Contemporary active surveillance: candidate selection, follow-up 82 tools, and expected outcomes. UrolClin North Am 2017;44:565-74. 83 3.

Kim, H.I., Jang, H.W., Ahn, H.S., et al. High serum TSH level is associated with 84 progression of papillary thyroid microcarcinoma during active surveillance. J Clin 85 EndocrinolMetab2017;doi:10.1210/jc.2017-01775. [Epub ahead of print]. 86 4.

Lee, Y.S., Lee, B.J., Hong, H.J., Lee,K.D.. Current trends of practical issues concerning 87 micropapillary thyroid carcinoma: the Korean Society of Thyroid-Head and Neck 88 Surgery. Medicine (Baltimore) 2017;96:e8596. 89 5.

Qian, K., Guo, K., Zheng, X., et al. Contrastive study of two screening criteria for 90 active surveillance in patients with low-risk papillary thyroid microcarcinoma: 91 a retrospective analysis of 1001 patients. Oncotarget2017;8:65836-46. 92 6.

Sun, H., Dionigi, G. Active surveillance for micro-papillary thyroid carcinoma:who are candidates, how should they be followed, when should they be treated, andwhat are the clinical and pathologic outcomes after delayed intervention.Surgery. 2018 Feb 15. pii: S0039-6060(18)30004-7.

Ito, Y., Uruno, R., Nakano, K., et al .An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003.13:381–388

Ito, Y., Miyauchi, A., Kihara, M., et al.Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014. 24:27–34

Kwon, H., Oh, H.S., Kim, M., et al. Active surveillance for patients with papillary thyroid microcarcinoma: a single center’s experience in Korea. J ClinEndocrinolMetab 2017. 102:1917–1925

Tuttle, R.M., Fagin, J.A., Minkowitz, G., et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JamaOtolaryngol Head NeckSurg. 2017. 143:1015–1020

Miyauchi, A., Kudo, T., Ito, Y., Oda, H., Sasai, H., Higashiyama, T., et al. Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance. Surgery. 2018;163(1):48-52..

Gao, M., Ge, M., Ji, Q., Cheng, R., Lu, H., Guan, H., Gao, L., et al. Chinese Association Of ThyroidOncologyCatoChinese Anti-CancerAssociation. 2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma. CancerBiolMed. 2017;14(3):203-211.

Takami, H., Ito, Y., Okamoto, T., et al. Revisiting the guidelines issued by the Japanese Society of Thyroid Surgeons and Japan Association of Endocrine Surgeons: a gradual move towards consensus between Japanese and western practice in the management of thyroid carcinoma. World J Surg 2014(38):2002–2010

Perros, P., Colley, S., Boelaert, K., et al. Guidelines for the management of thyroid cancer. ClinEndocrinol 2014 (Oxf ) 81(Suppl. 1):1–122.

AWMF (Hrsg) (2012) Operative Therapie maligner Schilddrüsenerkrankungen (online: www.awmf. org)

Merdad, M., Eskander, A., De Almeida, J., Freeman, J., Rotstein, L., Ezzat, S., et al. Current management of papillary thyroid microcarcinoma in Canada. J Otolaryngol Head Neck Surg. 2014 14;43:32.

Tufano, R.P., Bishop, J., Wu, G. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope 2012;122: 1634–40.

Al-Saif, O., Farrar, W.B., Bloomston, M., et al. Long-term efficiency of lymph node re- operation for persistent papillary thyroid cancer. J ClinEndocrinolMetab 2010; 95:2187–94.

Udelsman, R. Treatment of persistent or recurrent papillary carcinoma of the thyroid—the good, the bad, and the unknown. J ClinEndocrinolMetab 2010;95: 2061–3.

Lewis, B.D., Hay, I.D., Charboneau J.W., et al. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. Am J Roentgenol2002;178:699–704.

Lim, C.Y., Yun, J.S., Lee, J., et al. Percutaneous ethanol injection therapy for locally recurrent papillary thyroid carcinoma. Thyroid 2007;17:347–50.

Monchik, J.M., Donatini, G., Iannuccilli, J., et al. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well- differentiated thyroid carcinoma. AnnSurg2006;244:296–304.

Dionigi, G., Duran-Poveda, M. New approaches in thyroid surgery: is there an increased risk of nerve injury? Ann SurgOncol. 2011 Dec;18 Suppl3:S252-3. doi: 10.1245/s10434-011-1869-y. Epub 2011 Jun 30. PubMed PMID: 21717242.

Dionigi, G., Boni, L., Duran-Poveda, M. Evolution of endoscopic thyroidectomy. SurgEndosc. 2011 Dec;25(12):3951-2; author reply 3953. doi: 10.1007/s00464-011-1763-5. PubMed PMID: 21667208.

Dionigi, G. Evidence-based review series on endoscopic thyroidectomy: real progress and future trends. World J Surg. 2009 Feb;33(2):365-6. doi: 10.1007/s00268-008-9834-z. PubMed PMID: 19034568.

Dionigi, G., Chai, Y.J., Tufano, R.P., Anuwong, A., Kim, H.Y. Transoral endoscopic thyroidectomy via a vestibular approach: why and how? Endocrine. 2018 Feb;59(2):275-279. doi: 10.1007/s12020-017-1451-x. Epub 2017 Oct 16. PubMed PMID: 29039144.

Dinauer, C.A., Breuer, C., Rivkees, S.A. Differentiated thyroid cancer in children: diagnosis and management. CurrOpinOncol2008;20:59–65.

Hogan, A.R., Zhuge, Y., Perez, E.A., et al. Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Res 2009;156:167–72.

McNally, R.J.Q., Blakey, K., James, P.W., et al. Increasing incidence of thyroid cancer in Great Britain, 1976-2005: age-period-cohort analysis. Eur J Epidemiol 2012; 27:615–22.

Zimmerman, D. Thyroid carcinoma in children and adolescents: diagnostic implications of analysis of the tumor genome. CurrOpinPediatr2013;25:528–31.

Niedziela, M. Pathogenesis, diagnosis and management of thyroid nodules in children. EndocrRelatCancer2006;86:427–53.

LaQuaglia, M.P., Black, T., Holcomb, G.W, et al. Differentiated thyroid cancer: clinical characteristics, treatment, and outcomes in patients under 21 years of age who present with distant metastases. A report from the surgical discipline committee of the children’s cancer group. J PediatrSurg2000;35:955–60.

Rachmiel, M., Charron, M., Gupta, A., et al. Evidence based review of treatment and follow-up of pediatric patients with differentiated thyroid carcinoma. J PediatrEndocrinolMetab2006;19:1377–93.

Newman, K.D., Black, T., Heller, G., et al. Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis. A report from the surgical discipline committee of the children’s cancer group. AnnSurg 1998; 227:533–41.

Demidchik, I., Kontratovich, V.A. Repeat surgery for recurrent thyroid cancer in children. VoprOnkol2003;49:366–9.




DOI: https://doi.org/10.6092/1828-6550/APMB.106.2.2018.SD2

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Pino Antonella, Ettore Caruso, Antonina Catalfamo, Fausto Famà, Francesca Pia Pergolizzi, Alessandro Pontin, Gianlorenzo Dionigi

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.